Financial Performance - In 2019, the company achieved operating revenue of RMB 3,757.2 million, representing a year-on-year growth of 29.2%[7] - The gross profit for 2019 was RMB 1,331.7 million, an increase of 40.5% compared to the previous year, with a gross margin of 35.4%[7] - The net profit attributable to the parent company was RMB 547.2 million, reflecting a significant increase of 62.8% year-on-year[7] - The company reported total revenue of approximately RMB 3,757.2 million for the year ended December 31, 2019, an increase of 29.2% compared to RMB 2,908.1 million for the year ended December 31, 2018[10] - Gross profit for the reporting period was approximately RMB 1,331.7 million, up from RMB 948.1 million in the previous year, resulting in a gross margin increase from 32.6% to 35.4%[11] - Profit attributable to equity holders of the parent was approximately RMB 547.2 million, representing a 62.8% increase from RMB 336.0 million for the year ended December 31, 2018[11] - Adjusted net profit attributable to equity holders of the parent was approximately RMB 549.1 million, a 75.3% increase compared to RMB 313.2 million in the previous year[11] - The company achieved a revenue of RMB 3,757.2 million for the reporting period, representing a year-on-year growth of 29.2%[21] - The adjusted net profit attributable to the parent company was RMB 549.1 million, an increase of 75.3% compared to the end of 2018[21] Strategic Expansion - The company strategically expanded into clinical research services, enhancing its R&D service capabilities and operational efficiency[7] - The company expanded its client base to 1,038 clients, including 192 new clients, serving major global pharmaceutical companies[8] - The company strategically expanded its clinical services in China, including the acquisition of Nanjing SIR Biotechnology Co., Ltd. and investment in Beijing Lianstar Pharmaceutical Technology Development Co., Ltd.[8] - The company aims to enhance its integrated R&D service platform and expand its global footprint as part of its "New Five-Year Plan" starting in 2020[9] - The company is expanding its services to include clinical research and CMC services, enhancing its integrated drug development capabilities[18] - The company plans to complete the first phase of its Shaoxing factory, covering 81,000 square meters, by 2022 to support downstream clinical and commercial production services[8] Workforce and Talent Development - The company has over 7,000 employees across China, the United States, and the United Kingdom, supporting its integrated service platform for drug development[6] - The company expanded its CMC service team to 1,544 employees, an increase of 198 from December 31, 2018[22] - The company has a strong technical team of 992 professionals and over 6,400 scientists and R&D personnel across China, the UK, and the US as of December 31, 2019[34] - The company emphasizes talent development through internal training systems and partnerships with renowned laboratories[34] - The company plans to recruit more scientists and technical personnel in 2020 to expand its capabilities in biopharmaceuticals[39] Research and Development - The company focuses on accelerating drug innovation and contributing to health through its comprehensive R&D services[7] - The drug development service platform includes GLP-compliant drug safety evaluation services, chemical and formulation process development, and GMP production services[18] - The company has established a strong track record in providing R&D solutions to partners in North America, Europe, Japan, and China[6] - The company completed 29 clinical trial applications for innovative drugs in China, with 21 applications submitted across multiple jurisdictions including China, the US, and Europe[8] - The company is committed to improving its confidentiality policies and internal training to protect intellectual property[41] Governance and Compliance - The company has a strong governance structure with non-executive directors providing strategic guidance, including Mr. Chen, Mr. Hu, Mr. Li, and Mr. Zhou[53][54][55] - The company has complied with the Corporate Governance Code since its listing date on November 28, 2019[68] - The board consists of 12 members, including 3 executive directors, 4 non-executive directors, and 5 independent non-executive directors[68] - The company has established a system for the appointment, re-election, and removal of directors, with a three-year term for directors[74] - The company has established a comprehensive risk management framework, with the board of directors responsible for evaluating and determining acceptable risk levels to achieve strategic goals[90] Environmental, Social, and Governance (ESG) - In 2019, the company established an ESG management system and formed a social responsibility committee to oversee ESG-related matters[131] - The company received 287 valid responses from stakeholders in a sustainability survey, identifying compliance operations, occupational health and safety, pollution reduction, and anti-corruption as highly significant issues[139] - The company is committed to green operations, energy conservation, and employee development as part of its sustainability strategy[129] - The company has established an animal welfare and ethical review team to regularly assess animal welfare conditions[169] - The company has implemented strict animal welfare standards, ensuring that 100% of staff involved in animal management are certified and trained[169] Financial Management - The company has engaged Ernst & Young as its international and domestic auditors, with details of the audit and non-audit service fees provided in the financial report[88] - The total revenue from audit services amounted to RMB 3,480,000, while non-audit services generated RMB 4,806,600, leading to a total of RMB 8,286,600[89] - The company reported a net amount of approximately RMB 4,522.7 million raised from its global offering, which has not yet been utilized as of December 31, 2019[99] - 30% of the net proceeds from the global offering, amounting to RMB 1,356.8 million, is allocated for expanding laboratory and production capacity in China[100] - The company plans to distribute cash dividends amounting to no less than 20% of the total dividends distributed in the same period, provided there are no significant capital expenditures or investments in the next 12 months[85] Market Trends and Opportunities - The global drug service market is projected to grow from $94.4 billion in 2019 to $147 billion by 2023, with a compound annual growth rate (CAGR) of 10.3%[35] - The Chinese drug service market is expected to reach $10.8 billion by 2023, growing at a significantly faster rate than the global market[35] - The increasing number of biotech startups and their R&D spending presents significant growth opportunities for the company in the pharmaceutical development sector[33] - The demand for pharmaceutical R&D outsourcing services is strong in China, driven by a shift from generic drugs to innovative drugs among large pharmaceutical companies[33] Community Engagement and Social Responsibility - The company invested approximately 1.015 million yuan in social welfare projects in 2019, with a total of 100 hours dedicated to public service[198] - The company’s social responsibility initiatives include community engagement and charitable donations, reflecting its commitment to social welfare[129] - The company has received AAALAC certification and NIH animal welfare audit certification for its facilities in 2019[169] - The company actively opposes any form of forced labor and provides channels for employee complaints, ensuring a harmonious labor relationship[172]

康龙化成（北京）新药技术股份有限公司 2019 年年度报告全文 1 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2019 年年度报告 公告编号：2020-032 2020 年 03 月 康龙化成（北京）新药技术股份有限公司 2019 年年度报告全文 积金向全体股东每 10 股转增 0 股。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人(会 计主管人员)李承宗声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 公司在本报告"第四节经营情况讨论与分析"中"九、公司未来发展的展望" | --- | |------------------------ ...

康龙化成（北京）新药技术股份有限公司 2018 年年度报告全文 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2018 年年度报告 公告编号：2019-020 1 2019 年 04 月 康龙化成（北京）新药技术股份有限公司 2018 年年度报告全文 公积金向全体股东每 10 股转增 0 股。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人(会 计主管人员)李承宗声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 公司在本报告第四节经营情况讨论与分析中九、公司未来发展的展望 | --- | |--------------------------- ...